Adcetris (brentuximab vedotin)

P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology

The antibody-drug conjugate brentuximab vedotin (BV) has significantly improved outcomes for CD30-expressing lymphomas. The ECHELON-2 trial established BV combined with cyclophosphamide, doxorubicin, and prednisone (CHP) as a frontline standard for systemic anaplastic large cell lymphoma, demonstrating superior survival over the traditional CHOP regimen...We assess alternative strategies, such as BV-based combinations with immunotherapies or alternative chemotherapies, the integration of other targeted agents, and the transformative potential of advanced cellular treatments like anti-CD30 chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractory disease. The collective evidence signals a paradigm shift from a one-size-fits-all approach toward personalized, precision-driven strategies aimed at maximizing efficacy, minimizing toxicity, and improving long-term quality of life for patients with CD30-positive lymphomas.

This simple and reproducible method of generating D430B-ALCL spheroids to evaluate their response to Brentuximab Vedotin treatment, as here described, may provide a valuable preliminary tool for the future pre-clinical screening of patients' primary lymphoma cells or the development of novel therapies for this type of pathology and related diseases.

P=N/A, N=222, Completed, University Hospital, Bordeaux | Not yet recruiting --> Completed | Initiation date: Sep 2025 --> Feb 2025

P1/2, N=45, Completed, University of Washington | Active, not recruiting --> Completed

This case highlights the diagnostic challenge posed by rare penile lesions and, more importantly, the therapeutic dilemma of selecting an appropriate treatment for a disease that is localized yet multifocal. The successful outcome with systemic brentuximab vedotin plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, a deviation from standard guidelines for unifocal primary cutaneous anaplastic large cell lymphoma, underscores the need for individualized treatment strategies and further research to establish risk-adapted guidelines for this rare clinical entity.

P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026

P2, N=161, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2029 --> Dec 2026 | Trial primary completion date: Dec 2029 --> Dec 2026

Since CD30 can be targeted with brentuximab vedotin (BV), an anti-CD30 antibody linked with monomethyl auristatin E, a tubulin toxin, it is essential to gain a deeper understanding of the functions of CD30 in HTLV-1-infected cells in order to develop effective strategies for treating and preventing ATLL. This review describes the current understanding of how CD30 impacts the development of ATLL in cells infected with HTLV-1, with a specific emphasis on the connection between CD30 and the generation of abnormal lymphocytes.

Brentuximab vedotin (BV) plus cyclophosphamide, doxorubicin, and prednisone did not significantly improve OS or PFS overall; however, exploratory analysis indicated improved PFS in the KMT2A-r subset. KMT2A-r delineates an adverse-risk biology in nodal PTCL, aligns with non-TFH genomic hubs and markers of tumor burden, and may serve as a stratifier and hypothesis-generating target for BV-based strategies.

We describe the road to the discovery of the CD30 molecule and the way CD30 has contributed to more precise diagnosis and classification of lymphomas. Moreover, we address how anti-CD30 immunotherapy was developed and the impact of the anti-CD30-auristatin conjugate and anti-CD30 CAR-T cells in treating CD30-expressing lymphomas.

P2, N=20, Active, not recruiting, New York Medical College | Not yet recruiting --> Active, not recruiting